Aspen sells thrombosis drug

Drugmaker Aspen Pharmacare has agreed to sell the rights to its European thrombosis business to US pharmaceutical company Mylan for almost €642 million (about R12.8 billion).

“The transaction supports Aspen’s strategy of continuing to reshape the Group towards a greater concentration of revenue in emerging markets,” Aspen said. –